When a cancer diagnosis arrives, it often brings a flood of questions that extend far beyond chemotherapy regimens and surgical options. Patients want to know what they can do themselves: which herbs, oils, movement practices, or mind-body techniques might ease the punishing side effects of treatment, lift their quality of life, or even influence survival. In many cases, they begin searching for answers on their own, and what they find is a marketplace of complementary therapies of wildly varying quality and safety. A new prospective study from France, published in Supportive Care in Cancer, offers one of the clearest real-world portraits yet of how a structured integrative oncology consultation works inside a comprehensive cancer center, who walks through its door, and what those patients actually receive.
The study, known as THERAC, was conducted at the Léon Bérard Cancer Center in Lyon, one of France’s designated comprehensive cancer centers. Rather than relying on retrospective surveys or patient recall, the researchers collected data prospectively, using clinician-rated assessments at three fixed time points: at the moment of inclusion in the study, three months later, and six months later. This design matters because it captures the consultation process as it unfolds in routine clinical practice, not as patients remember it months or years afterward. Fifty patients attended an integrative oncology consultation during the study period, and their characteristics, requests, and referral pathways were systematically documented.
The demographic profile of the patients was strikingly skewed. Forty-five of the fifty attendees, or ninety percent, were women, and more than half, twenty-eight patients or fifty-six percent, were living with breast cancer. Twenty-two patients, forty-four percent, came from the wealthier metropolitan areas surrounding the center. These figures echo a persistent pattern documented across the complementary and alternative medicine literature: the patients who reach structured integrative oncology services are disproportionately female, disproportionately treated for breast cancer, and disproportionately drawn from more affluent, urban populations. The authors situate this within a broader body of French and international research on health inequalities, including studies showing that access to early-phase clinical trials in oncology is similarly shaped by social and geographic factors.
What did these patients actually want? The study recorded their motivations in detail, and the answers reveal a population seeking holistic engagement rather than a single miracle remedy. Thirty-seven patients, seventy-four percent, expressed a desire for comprehensive support, meaning they wanted their care considered as a whole rather than in fragments. Thirty-four patients, sixty-eight percent, said they wanted to improve their overall well-being, and thirty-three, sixty-six percent, specifically hoped to reduce the side effects of their cancer treatment. These motivations align with what previous systematic reviews have found: cancer patients typically turn to complementary approaches not to replace conventional medicine but to feel better while undergoing it, and often without telling their oncologists what they are doing.
That last point, the disclosure gap, is one of the most consequential findings in the wider field. Research cited by the THERAC team, including a systematic review of cancer patient disclosure and physician communication about complementary medicine use, has shown that many patients keep their use of supplements, herbal products, and alternative practitioners hidden from their medical teams. This silence is not trivial. Some herbal products and supplements can interact with chemotherapy or hormonal therapies, and unmonitored use can create genuine clinical risk. The integrative oncology consultation, in this framework, functions as a safe disclosure channel: a dedicated hour in which patients can talk openly about everything they are doing or considering, with a clinician trained to distinguish evidence-supported supportive practices from potentially harmful ones.
The structure of the consultation itself emerged clearly from the data. For forty of the fifty patients, or eighty-two percent, the first integrative oncology consultation lasted a full sixty minutes, an unusually generous allocation of time by the standards of modern oncology visits. Within that hour, clinicians most frequently prescribed aromatherapy, doing so for thirty-five patients, or seventy-four percent of those assessed. Aromatherapy has been progressively implemented at the Léon Bérard center in recent years, and the THERAC data suggest it has become the workhorse of the institution’s integrative offerings, typically deployed against anxiety, nausea, sleep disturbance, and other treatment-related symptoms.
Referral to other supportive care services was equally central to the consultation’s function. Twenty-four patients, sixty-nine percent, were oriented toward psychological support, and twenty-two patients, sixty-three percent, were directed toward adapted physical activities, structured exercise programs tailored to patients’ capacities during and after cancer treatment. These referrals are significant because both psychological support and physical activity sit at the top of the evidence hierarchy in integrative oncology. The Society for Integrative Oncology and the American Society of Clinical Oncology have jointly issued clinical practice guidelines endorsing specific mind-body and exercise interventions for anxiety, depression, and other symptoms in adults with cancer, and the Lyon consultation appears to operate as a routing mechanism that connects patients to precisely these guideline-supported services rather than leaving them to navigate the wellness marketplace alone.
Patient satisfaction with the process was remarkably high across the follow-up period. At the three-month assessment, twenty-seven of twenty-nine responding patients, ninety-three percent, reported being satisfied with the integrative oncology consultation. By six months, satisfaction among the eleven patients still responding was one hundred percent. The declining number of respondents at later time points is a familiar limitation of longitudinal observational studies, and the authors are candid that the sample is small and drawn from a single center, which constrains how far the findings can be generalized. Still, the consistency of positive evaluations suggests that the consultation model, with its long format and multidisciplinary referral capacity, meets a real and previously unmet need among the patients who access it.
Perhaps the most sobering conclusion of the study concerns equity and infrastructure. The authors found that referral to complementary therapies depended heavily on institutional resources and on the network connecting the cancer center to the surrounding city and hospital system. In other words, what a patient receives after an integrative oncology consultation is not determined solely by clinical need but by what services happen to exist locally and whether the institution has the staff and partnerships to deliver them. Combined with the observation that attendees were mostly women with breast cancer from affluent metropolitan areas, this points to a double filter: patients with time, information, and proximity are more likely to reach the consultation in the first place, and the services they are then referred to vary by geography and institutional capacity.
The THERAC team argues that a more transparent framework is needed for integrative oncology, one that provides appropriate management, ensures quality control, and limits potential abuses in a field where commercial interests often outpace the evidence. Their data sketch what such a framework looks like in practice: a dedicated consultation of about an hour, clinician-rated follow-up at fixed intervals, prescriptions restricted to therapies with supportive evidence such as aromatherapy, and active referral into psychological care and adapted physical activity. As demand for complementary approaches among cancer patients continues to grow worldwide, the Lyon experience suggests that the central challenge is not whether to offer integrative oncology, but how to build it so that the patients who need it most, not only those best positioned to ask for it, can reach it.
Subject of Research: Integrative oncology consultations and referral pathways to complementary therapies for cancer patients
Article Title: Integrative oncology consultation and patient referral to complementary therapies: results from the prospective study THERAC
Article References: Lochmann, M., Girodet, M., Charton, E., Bouvier, C., Fayet, Y., Fuentes-Vallejo, M., Chvetzoff, G., Christophe, V., & Mastroianni, B. (2026). Integrative oncology consultation and patient referral to complementary therapies: results from the prospective study THERAC. Supportive Care in Cancer, 34(10), Article 970. https://doi.org/10.1007/s00520-026-11217-5
Image Credits: AI Generated
DOI: 10.1007/s00520-026-11217-5
Keywords: integrative oncology, complementary therapies, supportive care, cancer, aromatherapy, breast cancer, patient referral, health inequalities, psychological support, adapted physical activity, prospective study, quality of life
News Source: Nathaniel Bowman. (October 13, 2026). Inside the Integrative Oncology Clinic: Who Seeks Complementary Cancer Care and What They Receive. Scienmag.
